End demand driving most of the increase in overseas sales
First written in FY2018-Q1. 2 of 25 entries say "Restated". Latest entry: FY2026.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Overseas sales increased in both the cardiovascular and non-cardiovascular fields, with foreign exchange movements also contributing. Cardiovascular sales increased in all regions, led by PCI guidewires and penetration catheters. In the non-cardiovascular field, abdominal and peripheral vascular products grew in all regions, while cerebrovascular products also increased across overseas markets, resulting in higher sales.」
In overseas markets, both the cardiovascular and non-cardiovascular fields grew. Cardiovascular sales increased in all regions, while non-cardiovascular sales also increased, led by abdominal and peripheral vascular products. - FY2026-H1Updated regional and product sales changes for the interim periodAnnual report
「Overseas sales increased in both the cardiovascular and non-cardiovascular fields. Cardiovascular sales increased in all regions, led by PCI guidewires. In the non-cardiovascular field, although sales of neurovascular and abdominal vascular products declined in China, sales of peripheral and abdominal vascular products increased in the US, Europe, and Asia, resulting in higher sales overall.」
Overseas sales increased in both the cardiovascular and non-cardiovascular fields. Cardiovascular sales increased in all regions, while increases in the US, Europe, and Asia more than offset declines in some products in China in the non-cardiovascular field. - FY2025-H1Explicit disclosure of the comparative impact of concentrated orders in the previous yearAnnual report
「Although the previous first-quarter consolidated accounting period included concentrated, one-time orders covering the full year from a distributor in Eastern Europe in the European region, revenue in the cardiovascular business performed extremely well across all regions, led by PCI guidewires and penetration catheters.」
The company explicitly identified as a comparative factor that the same period of the previous year included concentrated temporary orders from Eastern European distributors covering the full year, while explaining that cardiovascular sales remained strong in all regions even after taking this into account. - FY2024Updated to reflect full-year growth driven by market recovery, stronger foreign currencies, and expanded market shareAnnual report
「The Group’s net sales for the consolidated fiscal year increased 19.4% year on year to ¥10,754.7 million, as overseas sales grew significantly, reflecting the increase in cases accompanying the recovery from the COVID-19 pandemic, continued efforts to expand market share and the impact of a stronger foreign currency.」
The explanation of the factors behind higher overseas sales was updated to combine market recovery, higher case volumes, expanded market share, and stronger foreign currencies. - FY2024-Q3Updated to reflect higher overseas sales driven by market recovery, stronger foreign currencies, and stronger market needsAnnual report
「The group's sales for the nine months ended the third quarter increased substantially, mainly due to overseas sales, reaching ¥80.733 billion, up 15.7% year on year, as the impact of COVID-19 had almost disappeared, markets recovered and expanded, foreign currencies strengthened, and market needs increased.」
The explanation of the factors behind higher overseas sales was updated from the previous focus on concentrated orders and temporary factors to one centred on market recovery and expansion, stronger foreign currencies, and stronger market needs. Consolidated sales were ¥80.733 billion, up 15.7% year on year. - FY2024-Q2RestatedAnnual report
「The cardiovascular field progressed steadily, led by PCI guidewires and penetrating catheters. In Europe, particularly Eastern Europe, and China, concentrated orders, including pull-forward orders, from distributors and others led to an increase. However, sales increased in all regions even excluding these transactions.」
The company reconfirmed that concentrated orders, including pull-forward orders, from distributors and others in Eastern Europe and China contributed to the increase, while sales still increased in all regions excluding those transactions. - FY2024-Q1Additional disclosure of concentrated orders and growth across all regions excluding themAnnual report
「In Europe, particularly Eastern Europe, and China, concentrated orders, including pull-forward orders, from distributors and others led to an increase. However, sales increased in all regions even excluding these transactions.」
The company explained that concentrated orders, including pull-forward orders, from distributors and others in Eastern Europe and China contributed to the increase, while sales still increased in all regions excluding those transactions. - FY2023Reorganisation of the factors behind full-year growth in overseas salesAnnual report
「The group's sales for the fiscal year were ¥90.101 billion, up 15.9% year on year, as the impact of the decline in case volumes caused by COVID-19 was easing in many regions, the yen depreciated, and market penetration of the group's products was particularly strong in overseas medical markets.」
The explanation of the factors behind higher overseas sales was reorganised from one centred on end-user demand to one combining the recovery in case volumes, yen depreciation, and strong market penetration. Full-year sales were ¥90.101 billion. - FY2023-Q3Updated third-quarter market recovery, yen depreciation, and stronger market needsAnnual report
「Against this backdrop, the group's sales for the nine months ended the third quarter increased substantially, mainly due to overseas sales, as market size recovered year on year from the contraction caused by COVID-19, the yen depreciated, and market needs increased, reaching ¥69.774 billion, up 23.1% year on year.」
Against a backdrop of market recovery, yen depreciation, and stronger market needs, overseas sales increased substantially. Consolidated sales were ¥69.774 billion, up 23.1% year on year. - FY2023-Q2Updated second-quarter market recovery, yen depreciation, and stronger market needsAnnual report
「Against this backdrop, the group's sales for the six months ended the second quarter increased substantially, mainly due to overseas sales, as market size recovered year on year from the contraction caused by COVID-19, the yen depreciated, and market needs increased, reaching ¥45.435 billion, up 20.5% year on year.」
Overseas sales increased substantially due to market recovery, yen depreciation, and stronger market needs. Consolidated sales were ¥45.435 billion, up 20.5% year on year. - FY2023-Q1Additional disclosure of first-quarter market recovery, yen depreciation, and stronger market needsAnnual report
「Against this backdrop, the group's sales for the fiscal year increased substantially, mainly due to overseas sales, as market size recovered year on year from the contraction caused by COVID-19, the yen depreciated, and market needs increased, reaching ¥22.658 billion, up 25.0% year on year.」
In the first quarter, overseas sales increased substantially against a backdrop of recovery in the market size reduced by COVID-19, yen depreciation, and stronger market needs. Consolidated sales were ¥22.658 billion, up 25.0% year on year. - FY2022Additional disclosure of full-year market recovery and acquisition effectsAnnual report
「The group's sales for the fiscal year were ¥77.748 billion, up 26.4% year on year, as overseas sales increased substantially, particularly in Europe and China, due to the recovery in market size from the contraction caused by COVID-19, the yen's depreciation, stronger market needs, the effects of multiple acquisitions, and the promotion of direct sales in Germany.」
Overseas sales increased substantially for the full year against a backdrop of market recovery, yen depreciation, stronger market needs, the effects of multiple acquisitions, and the shift to direct sales in Germany. - FY2022-Q3Additional disclosure of the impact of the Russia-Ukraine situationAnnual report
「Non-cardiovascular fields also performed well, led by peripheral vascular products, neurovascular products, and OEM products. Although the deterioration of the Russia-Ukraine situation had an impact, its year-on-year impact was minor.」
In addition to explaining higher sales driven by overseas market recovery, the effects of acquisitions, and the shift to direct sales, the company newly disclosed the impact of the deteriorating Russia-Ukraine situation. It described the impact as minor. - FY2022-Q1Higher overseas sales driven by market recovery and acquisitionsAnnual report
「In overseas markets, across all regions, the contraction in market size caused by COVID-19 was trending toward recovery year on year, and market needs were increasing. As a result, business progressed very favorably, led by PTCA guidewires and penetrating catheters.」
The company explained that market contraction was recovering year on year in all regions, and that overseas sales increased substantially against a backdrop of stronger market needs and completed acquisitions. - FY2021RestatedAnnual report
「In overseas markets, the number of cases declined year on year, particularly in Europe and Asia, due to the impact of COVID-19. However, sales of cardiovascular PTCA guidewires and penetrating catheters increased as a result of stronger promotional activities in China and the promotion of direct sales in the US. Sales of neurovascular products also increased in the US, China, and Europe and the Middle East, resulting in higher sales overall.」
The company explained that overseas medical sales increased despite continued declines in case volumes, driven by promotional activities in China, the promotion of direct sales in the US, and higher sales of neurovascular products. - FY2021-Q3Additional disclosure of higher medical sales driven by stronger overseas promotionAnnual report
「In the medical business, despite the continued stagnation in the recovery of case volumes due to the impact of COVID-19, the company secured higher sales through measures including stronger promotional activities in overseas markets.」
The company explained that, although the recovery in case volumes remained stalled, the medical business secured higher sales through stronger promotional activities in overseas markets. - FY2021-Q2Product-specific increases presented alongside the global decline in case volumesAnnual report
「In overseas markets, sales increased for cardiovascular PTCA guidewires and penetrating catheters in China, neurovascular guidewires in the US and China, and peripheral vascular guidewires supplied through OEM transactions in the US. However, sales declined due to the impact of the global decline in case volumes caused by COVID-19.」
The company explained that, although sales volumes increased for some products and in some regions, overseas sales declined due to the global decrease in case volumes. - FY2021-Q1Additional disclosure of the recovery trend in case volumesAnnual report
「The decline has now passed its peak, and the number of cases is also trending toward recovery globally. However, the outlook remains uncertain.」
The company added that, with respect to the decline in case volumes caused by COVID-19, the global decline had passed its peak and was trending toward recovery. However, first-quarter sales declined due to the contraction in market size. - FY2020COVID-19 impact expanded to all regionsAnnual report
「In overseas markets, in addition to foreign-exchange effects, the number of cases declined in all regions, beginning with China, during the second half due to the impact of COVID-19. For the full year, however, sales increased because unit sales of cardiovascular PTCA guidewires rose in all regions, particularly in the US, and sales of neurovascular guidewires increased in China.」
The explanation of overseas demand expanded from a temporary contraction in the Chinese market to declining case volumes in all regions, beginning with China. For the full year, however, overseas sales increased due to higher product volumes. - FY2020-Q3Additional disclosure of the temporary contraction in the Chinese market due to COVID-19Annual report
「In the Chinese market, the number of endovascular treatment cases has been trending lower due to the impact of COVID-19. However, during the third quarter accounting period, shipments continued at the request of distributors, and the decline in sales was not proportional to the number of cases in the market, resulting in only a limited negative impact.」
The explanation of overseas demand was expanded to include the temporary factor of declining case volumes in China, while stating that the impact on sales was limited because shipments continued at distributors' request. - FY2019-Q2China explicitly identified as the main region for temporary factorsAnnual report
「In overseas markets, demand for PTCA guidewires and penetrating catheters in the cardiovascular field is trending higher in China, Europe and the Middle East, and Asia, and business is progressing steadily. We believe that one reason for the strong demand is that the increase includes temporary factors, such as special-demand events, mainly in the Chinese market.」
The company identified China, Europe and the Middle East, and Asia as regions where demand for overseas products was increasing, and explained that temporary factors, such as special-demand events, were concentrated mainly in the Chinese market. - FY2019-Q1Reorganisation of the regional breakdown of temporary factorsAnnual report
「In overseas markets, demand for PTCA guidewires and penetrating catheters in the cardiovascular field is trending higher in China, Europe and the Middle East, and Asia, and business is progressing steadily. We believe that some of the increase includes not only stronger end-user demand but also temporary factors, such as special-demand events.」
The company identified China, Europe and the Middle East, and Asia as regions where demand for overseas products was increasing, and stated that some of the increase included temporary factors, such as special-demand events, beyond end-user demand. - FY2018-Q3Expansion of the regions affected by temporary factorsAnnual report
「In overseas markets, PTCA guidewires and penetrating catheters in the cardiovascular field are trending higher across all regions. In the US, Europe and the Middle East, and China, the increase includes not only stronger end-user demand but also temporary factors, such as special-demand events.」
The explanation was expanded to cover the upward trend in overseas products across all regions, with the US newly identified as a region where the increase included temporary factors, such as special-demand events. - FY2018-Q2Additional disclosure of temporary factorsAnnual report
「In overseas markets, PTCA guidewires and penetrating catheters in the cardiovascular field are trending higher, mainly in Europe and the Middle East, China, and Asian markets. In Europe and the Middle East and in China, the increase includes not only stronger end-user demand but also temporary factors, such as special-demand events.」
The company explained that, in addition to end-user demand, the increase in overseas sales included temporary factors, such as special-demand events, in Europe and the Middle East and in China, supplementing its previous explanation that the increase was primarily driven by end-user demand. - FY2018-Q1First statedAnnual report
「Some of the increase includes temporary factors, such as distributors building inventory and special-demand events, but we understand that most of it was generally attributable to stronger end-user demand.」
The company explained that the increase in overseas market sales included temporary factors, such as distributor inventory building and special-demand events, while most of the increase was generally attributable to stronger end-user demand.